Scand J Rheumatol 20: 28&287, 1991
Improved Cost-effectiveness Ratio with a Patient Self-adjusted Naproxen Dosing Regimen in Osteoarthritis Treatment T. K. KVIEN’), 0. BRBRS2),P. H. STAFF3),S. ROGNSTAD4) and J. NORDBY’) “Oslo City Department of Rheumatology, Norwegian Lutheran Hospital; Department of Pharmacology, University of Oslo; ”Department of Physical Medicine and Rehabilitation, Ullevdl University Hospital, Oslo; 4, Lillestr0m; and 5’SyntexAIS, Str#rnrnen, Norway.
Scand J Rheumatol Downloaded from informahealthcare.com by McMaster University on 02/13/15 For personal use only.
Kvien TK, Br0rs 0, Staff PH, Rognstad S and Nordby J. Improved cost-effectiveness ratio with a patient self-adjusted naproxen dosing regimen in osteoarthritis treatment. Scand J Rheumatol 1991; 20: 280-287. A standard fixed dosing regimen (S) and a variable dosing regimen (VD) of naproxen for patients with knee and hip osteoarthritis were compared in a multicentre, open, controlled, parallel 8-week trial. The daily dose of naproxen (NaprosynR) in the S-group was 500-1000 mg, in VD maximum daily dose was 1000 mg. The number of patients entering the study was 396 (286 females). Mean (SD) age was 67 (10) and 67 (11) years in the S- and VD-groups respectively. The number of patients available for efficacy analyses, including the withdrawals, was 356. Efficacy measures included pain on movement, night pain, morning stiffness, a functional index and patient’s and doctor’s overall assessments. Similar improvement was seen in both groups. The number of patients withdrawn due to adverse reactions in Sand VD was 35 and 23 respectively ( ~ ~ 0 . 0 5Group ). differences in drug consumption were highly significant (p
Improved Cost-effectiveness Ratio with a Patient Self-adjusted Naproxen Dosing Regimen in Osteoarthritis Treatment T. K. KVIEN’), 0. BRBRS2),P. H. STAFF3),S. ROGNSTAD4) and J. NORDBY’) “Oslo City Department of Rheumatology, Norwegian Lutheran Hospital; Department of Pharmacology, University of Oslo; ”Department of Physical Medicine and Rehabilitation, Ullevdl University Hospital, Oslo; 4, Lillestr0m; and 5’SyntexAIS, Str#rnrnen, Norway.
Scand J Rheumatol Downloaded from informahealthcare.com by McMaster University on 02/13/15 For personal use only.
Kvien TK, Br0rs 0, Staff PH, Rognstad S and Nordby J. Improved cost-effectiveness ratio with a patient self-adjusted naproxen dosing regimen in osteoarthritis treatment. Scand J Rheumatol 1991; 20: 280-287. A standard fixed dosing regimen (S) and a variable dosing regimen (VD) of naproxen for patients with knee and hip osteoarthritis were compared in a multicentre, open, controlled, parallel 8-week trial. The daily dose of naproxen (NaprosynR) in the S-group was 500-1000 mg, in VD maximum daily dose was 1000 mg. The number of patients entering the study was 396 (286 females). Mean (SD) age was 67 (10) and 67 (11) years in the S- and VD-groups respectively. The number of patients available for efficacy analyses, including the withdrawals, was 356. Efficacy measures included pain on movement, night pain, morning stiffness, a functional index and patient’s and doctor’s overall assessments. Similar improvement was seen in both groups. The number of patients withdrawn due to adverse reactions in Sand VD was 35 and 23 respectively ( ~ ~ 0 . 0 5Group ). differences in drug consumption were highly significant (p
